Message-ID: <6951276.1075862885035.JavaMail.evans@thyme>
Date: Mon, 5 Nov 2001 12:56:27 -0800 (PST)
From: brown_mary_jo@lilly.com
Subject: ISIS 3521 Release
Mime-Version: 1.0
Content-Type: text/plain; charset=us-ascii
Content-Transfer-Encoding: 7bit
X-From: BROWN_MARY_JO@LILLY.COM@ENRON
X-To: alfred.gilman@utsouthwestern.edu, george.fisher@kodak.com, jterzuoli@ibjwhitehall.com, karen.n.horn@marsh.com, Lay, Kenneth </O=ENRON/OU=NA/CN=RECIPIENTS/CN=KLAY>, kseifert@kcc.com, prendergast@mayo.edu, scb@purdue.edu, win.bischoff@ssmb.com
X-cc: 
X-bcc: 
X-Folder: \KLAY (Non-Privileged)\Lay, Kenneth\Inbox
X-Origin: Lay-K
X-FileName: KLAY (Non-Privileged).pst


We thought you might be interested in this ISIS press release regarding the compound we are developing with ISIS for the treatment of non-small cell lung cancer.
 

 - ISIS 3521 - AACR.NCI.EORTC Meeting - 10.29.doc 